MetaCap

Voyager Therapeutics Inc. (VYGR)

NASDAQ: VYGRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

1.53-0.08 (-4.97%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

VYGR stock chart

Technical analysis

Key statistics

All statistics
Market cap
$95.21M
EPS (TTM)
-$1.74
52-week range
1.48 – 5.48
Day range
1.51 – 1.65
Volume / Avg
639.24K / 770.24K
Beta
—

52-week range

$1.48$5.48

VYGR stock today

Voyager Therapeutics (VYGR) closed at $1.53 on Nov 20, down 4.97% (-$0.08), versus the S&P 500's 3.70% decline. At this level, VYGR sits near the bottom of its 52-week range of $1.48 to $5.48: 72.1% below the high, set on Mar 11, 2026 and 3.4% above the low. VYGR is down 61.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 63.4%.

Voyager Therapeutics has posted a net loss over the last twelve months (EPS of -$1.74), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Voyager Therapeutics

Company profile

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Alfred W. Sandrock Jr., M.D., Ph.D.
Headquarters
Lexington, MA
Employees
141
IPO year
2015

Financial highlights

Full financials

In fiscal 2025, Voyager Therapeutics generated $40.4 million in revenue, down 49.5% from fiscal 2024, its first annual decline since 2024. Voyager Therapeutics reported a net loss of $119.7 million, compared with a loss of $65.0 million a year earlier. Operating margin was -326.6%.

Voyager Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$40.37M$80.00M$250.01M$40.91M$37.41M
Growth-49.53%-68.00%+511.16%+9.33%-78.14%
Net income$-119.72M$-65.00M$132.33M$-46.41M$-71.20M
EPS (diluted)$-2.04$-1.13$2.97$-1.21$-1.89

Analyst forecast

Forecast

Consensus (11 analysts)

strong_buy

Avg. price target

$14.22+829.41%

  • Strong buy 0
  • Buy 11
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $8.00High $25.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 9, 2026
EPS actual vs est.
$-0.40 vs $-0.41
Surprise
+2.44%

VYGR news

All VYGR news

Voyager Therapeutics peers

Health Care sector
VYGR peer companies
CompanyPrice% ChgMarket capCompare
OTLKOutlook Therapeutics Inc.0.39-2.74%$94.94Mvs VYGR
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs VYGR
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs VYGR
LENZLENZ Therapeutics Inc.2.97-11.23%$93.16Mvs VYGR
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs VYGR
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs VYGR
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs VYGR
ARMPArmata Pharmaceuticals Inc.3.03+1.68%$112.69Mvs VYGR

Indexes, lists and sector

Voyager Therapeutics stock FAQ

What is Voyager Therapeutics's stock price today?

VYGR last traded at $1.53 as of Nov 20, 4:00 PM EST, down 4.97% on the day. Prices are delayed at least 15 minutes.

Who is Voyager Therapeutics's CEO?

Dr. Alfred W. Sandrock Jr., M.D., Ph.D. is the chief executive officer of Voyager Therapeutics Inc., which has about 141 employees.

What is the VYGR 52-week high?

The 52-week high for VYGR is $5.48 and the 52-week low is $1.48. The stock is currently 72.1% below its high.

Compare VYGR